Pharmaceutical & Healthcare | Kisaco Research

Pharmaceutical & Healthcare

Register for an event
Register for an event
Sponsor an Event
Sponsor an Event
Who’s Involved
Who’s Involved
Filter by:
 
26-27 Nov 2019
Frankfurt
 The Targeting RNA congress will discuss the latest advancements in modulation of RNA (splicing/non-coding/micro) directly with small molecules and through epigenetics. The meeting will showcase structures of small molecules binding to disease relevant RNA and innovations in building hit-to-lead RNA specific platforms both essential for proof-of concept.Bringing together leaders in academics and industry such as Novartis, Merck, Gotham Therapeutics and University of Cambridge, who are building platforms to identify and validate targets, in order to assess in disease relevance approaches in the relatively untapped RNA world. The meeting will also discuss translational strategies, addressing structural biology, biochemical and biophysical attributes, chemical hurdles associated with new drug discovery platforms.What to expect:Opportunities to engage with key players from biotech, pharma, and academia that are building platforms to target RNA with small molecules, modify the RNA with enzymes (epigenetics) and indirectly through protein-RNA interactions.Hear how to overcome 2D structural biology parameters from leading European RNA biologists and computational biologists and emerging European epigenetics companies.The first European translational event focusing on modifying RNA upstream regulation to enable preventive medicine instead of treating symptoms with small molecules and epitranscriptomics.A meeting bridging the gap between the key research challenges such as target identification (chemo-proteomics, 2D/3D structures) and validation (small molecule binding efficiencies, selectivity and stability) and sharing new methodologies and process for obtaining hit to lead products in the RNA space.
 
28-30 Jan 2020
London, UK
The market value for cell therapies is expected to triple in size by 2025 to $8.21 bn, with investment also having increased by 64% since 2017 to $7.6 bn. Cell therapies have a huge commercial potential however scaled manufacturing, automation, logistics, regulation, and quality control continue to be limiting factors. Before cell therapies can make a mainstream clinical impact, patient access increased and truly reach their commercial potential, these obstructions need to be improved. The Vein-to-Vein Congress will gather manufacturing, operations, site managers and logistical heads from both Biotechs and pharmaceutical companies to address these bottlenecks and facilitate the commercial manufacture of cell therapies. As the cell therapy industry shifts from manual to automated manufacturing, the Vein-to-Vein Congress will discuss the measures that leading companies have put in place to streamline their manufacturing process, scale-up over time and ensure a water-tight supply chain with tracking and trackability from cell collection to patient. 
 
CAR-T Congress EU 2020
29-30 Jan 2020
London, United Kingdom
Be part of the movement as CAR-T Therapy shapes the future of oncology.The promise of the revolutionary oncology treatment, CAR-T therapy, has become a reality this year, with end-stage cancer patients treated on public health services across the world. As CAR-T moves into the public domain, battle has commenced in the race to effectively commercialise this ground-breaking therapy.The CAR-T Congress is bringing together leading biotechs, late-stage researchers and global pharmaceutical leaders to promote and share research that will break down barriers in R&D through novel data. In our fourth annual congress, we are introducing a new pre-day focused on NK Cell Therapy and the event will run alongside our Vein-to-Vein Congress, so you can tailor your agenda and learn more about cell therapies and their manufacturing. Having listened to the market demands, this year we will be bringing you even more industry-driven understanding of translational applications of the science that drives R&D in CAR-T. Tackle the next hurdles for allogeneic treatments by limiting graft vs host disease through the use of iPSC, and increase the efficacy of these treatments in solid tumours through combination therapies and solid tumour manipulation.Talks run by biotechs, pharma and regulatory bodies, will put you in a position to make informed decisions when commercialising your CAR-T therapy.
 
North American Protein Degradation Congress
4-6 Feb 2020
San Diego, USA
“The entire bandwidth of the protein degradation field was covered with excellent, carefully prepared presentations” -  Peter von Matt, NovartisWith Arvinas’ PROTAC therapy entering phase 1 clinical trials, Kymeras’ IRAK4 degrader racing through pre-clinical, and Bristol-Myers Squibb approaching complete acquisition of Celgene, it has never been a more exciting time to be working in the field of targeted protein degradation.Following the global response to the inaugural European Congress earlier this year, the North American Protein Degradation Congress will bring together pharma, biotech, and academic researchers to expand upon one of the hottest drug discovery platforms within the pharmaceutical industry. Delegates will have the opportunity to learn from experts and key thought leaders within the protein degradation space, allowing ideas to be exchanged, partnerships to be built, and difficulties to be addressed in expanding the space of protein degraders beyond our current knowledge.At the congress, you can expect to hear the following:The latest pre-clinical and clinical data in PROTAC therapy and molecular gluesEmerging strategies outside of PROTACs and molecular glues to induce TPDAssessing rates of protein synthesis, degradation, and quantifying protein homeostatic in vivoInsights into protein degrader PK/PD from mechanistic modelling
 
5-6 Feb 2020
Washington D.C., USA
The inaugural Phage Futures Congress 2019 in Washington D.C was the first of its kind to discuss how to translate phage-based application in to clinically and commercially viable therapeutics.Join us in 2020 as we once again bring together over 250+ representatives from established biotech companies (from human and animal applications), new adopters, key academic researchers and big pharma. Expect to hear:Developments within phage applications across acute and chronic illnessesRegulatory discussions, including clinical trial landscape updatesUnderstanding of the animal health phage applications can translate into progressing human phage therapy commercialisation
 
OCTS 2020
7-8 Apr 2020
Boston, USA
Onco Cell Therapy Summit (OCTS), formerly the CAR-T Congress, is an event that brings industry together to share novel research, manufacturing techniques and regulatory best practice. Each session of OCTS 2020 is dedicated to translating your novel data assets & IP into commercially viable oncological therapies.OCTS is a 4-track event and whilst bringing together the key decision makers for CAR-T therapies, this year’s event will have an added focus on the ground breaking science that is driving the surge of interest in harnessing alternative cell therapies in cancer treatments.With 2 of our tracks comprised of research on CAR-T and alternative cell therapies, the other pillar in rolling out these therapies is increasing the affordability of the treatments. The other two tracks will delve into best practice in commercialization and manufacturing of immuno-oncological cell therapies.Each day of the summit will conclude in plenary room panels that spin out into bespoke roundtable discussions to break down the key challenges in major topics to R&D, manufacturing and commercialization.
 
CAR-T Congress USA 2020
7-8 Apr 2020
Boston, USA
The CAR-T Congress gathers thought leaders from biotech, big pharma, academia and investment to address the challenges and opportunities of CAR-T therapies in both liquid and solid tumors. Discussing the potential of CARs in alternative cell types, mechanisms behind toxicity and tumor targeting, this event will provide an in depth view into this expansive area.
 
Protein Engineering Congress USA 2020
22-23 Apr 2020
USA
Most enzymes found in nature are not suitable for industrial purposes. The field of protein and enzyme engineering is growing at a rapid rate, with competition within industries high and the need to optimize performance greater than ever. Introducing the European Protein Engineering Congress, dedicated to uncovering the new and emerging practices, techniques and methods of protein and enzyme engineering across industries.With pharmaceutical, flavour & fragrance, consumer goods, animal feed, and agrochemical sectors all approaching the design, build and generation of new biocatalysts and molecules not found in nature, come and learn from our line-up of leading speakers to get an update on the new technologies used in the field of strain and protein engineering. Are you tasked with API and natural product synthesis? Why not hear how the industry is applying biosynthetic pathway transfer and multi-model assembly strategies to generate new molecules for industrial purposes? Are you struggling to craft new enzymes never-before-seen in this century? Hear how ancestral sequence reconstruction, smart-library design, and computer-aided innovation can allow you to discover and generate new and stable active enzymes.Attend and you'll be able to; increase your product pipeline, increase product efficiency and increase differentiation by meeting the experts in the biocatalysis and protein engineering space.This is not your average protein engineering congress...it's about industry, sharing knowledge, and optimizing your protein engineering method for the best outcomes.
 
European Protein Degradation Congress 2020
12-13 May 2020
Basel, Switzerland
“Targeted protein degradation promises to be the greatest innovation in small molecule drug discovery in the new millennium.” - Manfred Koegl, Lab Head Oncology Research, Boehringer IngelheimWith capital investment coming in fast, industry is ready to commercialise the therapeutic potential of PROTACs and molecular glues to build safe, effective targeted protein degradation products. As Arvinas conducts the groundbreaking first PROTAC clinical trials this year, it could be only be a matter of time before PROTACs and molecular glues enter the market. The European Protein Degradation Congress will bring together leading industry players within big pharma and biotech along with expert academics in the ubiquitin space - providing an open forum and facilitate the sharing of in vitro and in vivo data, as well as build a deeper mechanistic understanding of the ubiquitin pathways and techniques to make the ‘undruggable’ druggable.Expect to hear strategies to overcome the structural biology, pharmacology and chemistry obstacles associated with the discovery and development of these bi-functional and single entity molecules.
 
Protein Engineering Congress EU 2020
10-11 Nov 2020
Frankfurt, Germany
Most enzymes found in nature are not suitable for industrial purposes. The field of protein and enzyme engineering is growing at a rapid rate, with competition within industries high and the need to optimise performance greater than ever. Introducing the European Protein Engineering Congress, dedicated to uncovering the new and emerging practices, techniques and methods of protein and enzyme engineering across industries.With pharmaceutical, flavour & fragrance, consumer goods, animal feed, and agrochemical sectors all approaching the design, build and generation of new biocatalysts and molecules not found in nature, come and learn from our line-up of leading speakers to get an update on the new technologies used in the field of strain and protein engineering. Are you tasked with API and natural product synthesis? Why not hear how the industry is applying biosynthetic pathway transfer and multi-model assembly strategies to generate new molecules for industrial purposes? Are you struggling to craft new enzymes never-before-seen in this century? Hear how ancestral sequence reconstruction, smart-library design, and computer-aided innovation can allow you to discover and generate new and stable active enzymes.Attend and you'll be able to; increase your product pipeline, increase product efficiency and increase differentiation by meeting the experts in the biocatalysis and protein engineering space.This is not your average protein engineering congress...it's about industry, sharing knowledge, and optimising your protein engineering method for the best outcomes.
Filter by:
 
Microbiome Congress 2019
13-14 Nov 2019
London, UK
The Annual European Microbiome Congress by Kisaco Research has become a trusted learning and networking platform and a true business community for microbiologists, clinicians regulatory and industry executives who require insight into the latest in microbiome research, clinical trials and collaborative partnerships.
 
Protein Engineering Congress
12-13 Nov 2019
Frankfurt, Germany
Most enzymes found in nature are not suitable for industrial purposes. The field of protein and enzyme engineering is growing at a rapid rate, with competition within industries high and the need to optimise performance greater than ever. Introducing the European Protein Engineering Congress, dedicated to uncovering the new and emerging practices, techniques and methods of protein and enzyme engineering across industries.With pharmaceutical, flavour & fragrance, consumer goods, animal feed, and agrochemical sectors all approaching the design, build and generation of new biocatalysts and molecules not found in nature, come and learn from our line-up of leading speakers to get an update on the new technologies used in the field of strain and protein engineering. Are you tasked with API and natural product synthesis? Why not hear how the industry is applying biosynthetic pathway transfer and multi-model assembly strategies to generate new molecules for industrial purposes? Are you struggling to craft new enzymes never-before-seen in this century? Hear how ancestral sequence reconstruction, smart-library design, and computer-aided innovation can allow you to discover and generate new and stable active enzymes.Attend and you'll be able to; increase your product pipeline, increase product efficiency and increase differentiation by meeting the experts in the biocatalysis and protein engineering space.This is not your average protein engineering congress...it's about industry, sharing knowledge, and optimising your protein engineering method for the best outcomes.
 
Personalized Nutrition 2019
26-27 Jun 2019
San Francisco, CA, USA
Hyperconnected and health-focused consumers are switching their purchasinghabits from a one-size-fits-all approach to personalized solutions, digital interfacesand on-demand manufacturing. The nutrition space is no exception. With increasingpopulations of ‘biohackers’ there is a demand to self quantify, pre-diagnose andconsume only foods designed to fit your daily macros. But how does the nutritionindustry provide for n=1?The Personalized Nutrition Innovation Summit showcases disruptive start ups infour main categories; biological data capture, data analysis, meal planning andsupplement providers.From personalized vitamins to AI-driven meal planning, we will be discussing how todevelop scalable, trackable and attainable personalized nutrition solutions.The summit brings together CEOs, CTOs, investors and founders across the nutritionindustry. Attend the summit to learn how to assess the current science behindpersonalized nutrition, the tools to strengthen recommendations and the steps tofoster partnerships in this multidisciplinary ecosystem.
 
Microbiome Invest 2019
23 May 2019
London
Microbiome Invest 2019 is dedicated to showcasing the most innovative emerging companies and academics with commercially viable research that manipulates the microbiome. Active investors and multinational nutrition and health companies will also share their knowledge and perspectives on commercialisation and discuss the most cutting-edge products and research in the microbiome space.
 
European Protein Degradation Congress
22-23 May 2019
Basel, Switzerland
“Targeted protein degradation promises to be the greatest innovation in small molecule drug discovery in the new millennium.” - Manfred Koegl, Lab Head Oncology Research, Boehringer IngelheimWith capital investment coming in fast, industry is ready to commercialise the therapeutic potential of PROTACs and molecular glues to build safe, effective targeted protein degradation products. As Arvinas conducts the groundbreaking first PROTAC clinical trials this year, it could be only be a matter of time before PROTACs and molecular glues enter the market. The European Protein Degradation Congress will bring together leading industry players within big pharma and biotech along with expert academics in the ubiquitin space - providing an open forum and facilitate the sharing of in vitro and in vivo data, as well as build a deeper mechanistic understanding of the ubiquitin pathways and techniques to make the ‘undruggable’ druggable.Expect to hear strategies to overcome the structural biology, pharmacology and chemistry obstacles associated with the discovery and development of these bi-functional and single entity molecules.
 
CAR-T Congress USA 2019
16-17 Apr 2019
Boston, USA
The CAR-T Congress gathers thought leaders from biotech, big pharma, academia and investment to address the challenges and opportunities of CAR-T therapies in both liquid and solid tumors. Discussing the potential of CARs in alternative cell types, mechanisms behind toxicity and tumor targeting, this event will provide an in depth view into this expansive area.
 
Human Biotech Animal Health 2019
9 Apr 2019
Hyatt Regency Boston Harbor, Boston, MA
Join the first ever conference connecting human biotechs with the animal health industry. Traditionally, innovation in veterinary health has come from parent human pharmaceutical R&D pipelines. Within an increasingly independent and mature animal health industry, new routes to innovation are being established. There are a multitude of exceptional technologies in the human health field that could be used in animal health, but currently there is limited contact between the two areas – this summit aims to connect the two industries.
 
20-21 Mar 2019
Boston, USA
Our speakers will explore ground-breaking developments surrounding CRISPR and utilising all genome editing tools as a therapy. It will focus on advancements to overcome ‘off targets’, delivery approaches for in vivo applications and efficacy considerations across patient diversity.CRISPR Therapeutics’ TJ Cradick and Cellectis’ Stefan Scherer will share their clinical trial experiences within therapeutic genome editing applicationsHarvard’s Richard Sherwood will share how to improve CRISPR safety by utilizing machine learningCasebia’s Abraham Scaria will offer delivery guidance to progress in vivo applicationsIn an extremely busy and exciting space it can be hard to pick out the top tool innovations to increase precision and properly discuss clinical challenges, this meeting will facilitate this. It will provide an opportunity with engage with the leading experts who are working on new platforms, leading the clinical trials and have patient insights. It is also a forum to build collaborations to create a clinically and commercially viable, effective and safe approach within gene and cell therapy medicine. ‘CRISPR medicines have the potential to transform the treatment for rare genetic and perhaps common diseases; the challenge for scientists is to demonstrate that these medicines can be both safe and effective’ – Steve Rees, VP of Discovery Biology, AstraZenecaSPEAKERS FROM 
 
CAR-T Congress EU 2019
30-31 Jan 2019
London, United Kingdom
CAR-T cell therapy has shown unparalleled success in haematological malignancies, paving the way for the field of immuno-oncology. In 2017 two therapies achieved FDA approval in the USA, and following recent approval by the EMA, it is a landmark time for the industry. Despite the huge successes there are still a number of hurdles to overcome before CAR-T can be effective in mainstream oncology beyond haematological malignancies. The European CAR-T Congress’ mission is to address the opportunities and challenges that presently face the CAR-T field, to maximise the potential of this ground-breaking therapy.Sessions include:Solid tumour targeting: overcoming the tumour microenvironmentMulti-specific & dual targeting CARsProcess development, scalability & automationAllogeneic vs Autologous: the potential of off-the-shelf therapiesPatient access, implementation & regulatory challengesAdvances in gene engineeringSafety and toxicity
 
29-30 Jan 2019
Washington DC, USA
The Phage Futures Congress will bring together peers from biotech companies and academia, along with experts from regulatory bodies, pharmaceutical companies and government institutions, to discuss how to actively progress clinical science and viable phage application routes to market. You will hear about:Regulatory guidance to achieve clinical data from Cara Fiore, FDAStrategies to access the market via the veterinary, personalized medicine and traditional pharmaceutical routesInsights into investment drivers for phage therapy from NIH and Boehringer IngelheimFacts on how to manufacture GMP phageApplications to overcome multi-drug resistance with combined approaches such as phage therapy and antibiotics "This congress has the potential to act as a catalyst to further cooperative and collaborative efforts to develop alternate Phage based approaches to the antibiotic crisis. In addition, the location in the Washington DC area will facilitate an opportunity for Government Agencies, responsible for public health, such as the NIH, FDA, USDA and DOD to participate and interact with educational research groups and biotechnology companies developing phage therapies and initiating clinical testing." - Carl Merril, Adaptive Phage Therapeutics
 
Personalised Nutrition Europe 2018
5-6 Dec 2018
London, UK
Personalised Nutrition Europe is dedicated to the innovators & disruptors in nutrition. Bringing together industry leaders with emerging companies & start-ups to discuss the potential of this growing field on public health. Meet the start-ups redefining diet, incorporating a wide range of analytics and technologies to provide insights into healthcare, and hear from global nutrition companies on how the technology revolution will impact the food industry & influence consumer trends.Personalised Nutrition Europe draws on industry leaders who discuss how to integrate existing and new types of data around health and disease to reveal informative and actionable insights. The Summit will teach you how to better acquire, understand and use your data to forge the key partnerships in this industry. Key Takaways:How can I scale up my product?How can I measure the performance of my nutritional intervention?How can I better target the consumer by understanding motivation behind nutrition choices?How can I partner with retailers and industry leaders?How do I use my data to forge partnerships in industry?How can I target my consumer better and ensure they adhere to nutritional plans?How to identify and incorporate the best science into my business?How can I produce high quality data with low cost testing?How can I improve my business strategy to capitalise on growing interest in personalisation?What policy changes do I need to consider to protect my business?
 
Microbiome Congress 2018
14-15 Nov 2018
London, UK
The Annual European Microbiome Congress by Kisaco Research has become a trusted learning and networking platform and a true business community for microbiologists, clinicians regulatory and industry executives who require insight into the latest in microbiome research, clinical trials and collaborative partnerships.
 
Personalized Nutrition Innovation Summit 2018
26-27 Jun 2018
San Francisco, CA, USA
The Personalized Nutrition Innovation Summit is dedicated to the innovators & disruptors in nutrition. Bringing together industry leaders with emerging companies & start-ups to discuss the potential of this growing field on public health. Meet the start-ups redefining diet incorporating a wide range of analytics and technologies to provide insights into healthcare, and hear from global nutrition companies on how the technology revolution will impact the food industry & influence consumer trends.5 key benefits of attending:• Enabling collaboration through dedicated networking sessions• Hear from the disruptors like Habit• Gain insight from major nutrition companies like Kellogg to understand their drivers• Understand from STYR Labs about making better babies through personalized nutrition and AI• Recognize the major consumer trends reshaping nutritionFeaturing breakthrough technologies, including:• Microbiome analytics• Genomics• Biomarkers• Biosensors & wearables• AI & Big data• Retail & eCommerce
 
Human Biotech Animal Health EU
18-19 Jun 2018
Amsterdam, The Netherlands
Join the first ever conference series connecting human biotechs with the animal health industry. Following the event's hugely successful launch in Boston, USA, Human Biotech & Animal Health Business Partnering Summit is now coming to Europe. Traditionally, innovation in veterinary health has come from parent human pharmaceutical R&D pipelines. Within an increasingly independent and mature animal health industry, new routes to innovation are being established. There are a multitude of exceptional technologies in the human health field that could be used in animal health, but currently there is limited contact between the two areas – this summit aims to connect the two industries.
 
Microbiome Invest 2018
23 May 2018
Novotel London West, London, UK
The Microbiome Invest Congress 2018 is dedicated to showcasing the most innovative emerging companies and academics with commercially viable research that manipulates the microbiome. Active investors, and multi-national nutrition and pharmaceutical companies will also share their knowledge and perspectives on commercialisation and discuss the most cutting-edge products and research in the microbiome space.
 
8-9 May 2018
Boston, USA
The influence of the microbiome on human health & disease has been a growing area of interest in recent years, however until recently the impact of the microbiome on the initiation, progression & treatment of cancer was unknown. In recent months research has uncovered the potential of the microbiome to improve cancer therapies and to be a useful tool for patient stratification and diagnostics. With a better understanding of the oncobiome there is the potential to improve patient outcomes and increase the efficacy of existing therapies and drugs.
 
CAR-T Congress USA
20-22 Mar 2018
Boston, USA
The CAR-T Congress gathers thought leaders from biotech, big pharma, academia and investment to address the challenges and opportunities of CAR-T therapies in both liquid and solid tumors. Discussing the potential of CARs in alternative cell types, mechanisms behind toxicity and tumor targeting, this event will provide an in depth view into this expansive area.
 
Human Biotech Animal Health Partnering
12-13 Mar 2018
Boston, USA
Join the first ever conference connecting human biotechs with the animal health industry. Traditionally, innovation in veterinary health has come from parent human pharmaceutical R&D pipelines. Within an increasingly independent and mature animal health industry, new routes to innovation are being established. There are a multitude of exceptional technologies in the human health field that could be used in animal health, but currently there is limited contact between the two areas – this summit aims to connect the two industries.
 
Artificial Intelligence: Transforming Pharma
21-22 Feb 2018
Boston, USA
The Artificial Intelligence: Transforming Pharma Congress will discuss AI's potential for more efficiently discovering medical trends and efficacious therapeutics and also for streamlining the development phase. We'll be sharing case studies and analysis into current AI partnerships and collaborations.
 
Combined CAR-T Congress 2018
30-31 Jan 2018
Berlin, Germany
CAR-T clinical trials have demonstrated unparalleled success achieving remission rates of up to 94% in multiple hematological malignancies…is CAR-T therapy what we’ve been waiting for?Join 18+ thought-leaders from biotech, big pharma, academia and the wider service community on 30th – 31st January 2018 at Europe’s first congress dedicated to addressing the challenges and opportunities of CAR-T therapies.Hear first-hand results from unpublished human and clinical studiesExplore the challenges of the tumour microenvironmentUnderstand how to implement a combined approach to cell therapyDiscover safety switch improvement strategiesNetwork with 100+ attendees to share knowledge and understand the commercial opportunities of CAR-TWith a 50:50 split of academia to industry, build relationships whilst being updated by 20+ amazing speakers from University Hospital of Cologne, Catapult, Cellectis and more on all of the latest developments in this exciting field. Get involved today.
 
3D Cell Models Congress
24-25 Jan 2018
Berlin, Germany
The 3D Cell Models Congress 2018 will present the latest developments and innovation in three-dimensional cell models including organoids, spheroids, and organ-on-a-chip, as well as bioprinting technologies.
 
European Microbiome Congress
27-29 Nov 2017
London, UK
The Annual European Microbiome Congress by Kisaco Research has become a trusted learning and networking platform and a true business community for microbiologists, clinicians regulatory and industry executives who require insight into the latest in microbiome research, clinical trials and collaborative partnerships.
 
Market Access for Cell & Gene Therapy
18-19 Oct 2017
London, UK
With the increase in the number of cell and gene therapies being developed and coming to market globally and the potential to revolutionise the treatment of disease, this summit will discuss strategies for pricing and contracting cell or gene therapies that will allow payers to fund these innovative and significantly beneficial therapies to result in rapid patient access.
 
Animal Health Asia 2017
18-19 Oct 2017
Grand Hyatt, Beijing, PRC
Animal Health Innovation Asia is the premier B2B conference showcasing innovative technologies within the livestock, aquaculture and companion animal health markets. Last year, over 160 senior-level executives and influencers joined us to engage with the industry and discuss financial investment, M&A and market access into Asia. Our 2017 event in Beijing had a special focus on China, with ten strategic partners from the region forming our Company Showcase - a chance for global companies to find new business partners from within China.
 
Aquaculture Innovation
27-28 Sep 2017
London, UK
The Aquaculture Innovation Summit is a new conference, as part of the Animal Health Innovation series, which focuses on showcasing and supporting innovation and sustainability initiatives in three key areas of aquaculture: farm management, nutrition and health.

Sponsorship Opportunities

At Kisaco Research we bring our clients both intensively researched conference programmes and the most influential networks. Kisaco Research genuinely helps its clients set and reset their business destinations and chart their own courses.

Benefits of Attending our Events

Meet industry peers that will help build a career-changing network for life.

MEET

industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes - ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

LEARN

from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

NOTE

down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest from the mistakes of your peers as much as their successes - ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

INVEST

both in your company growth and your own personal development by signing up to one of our events and get started.